Latest From Celmatix Inc.
Femtech, which describes digital technologies that aim to improve women's health, is expected to reach $50bn in market size by 2025, according to Frost & Sullivan. Reproductive health and menstrual health trackers are two of the fastest-growing sectors in femtech. We've highlighted some of the biggest players in both segments, their innovative business models, plans and also looked at barriers such as privacy issues, accuracy of mobile applications and funding challenges.
Ferring announced this morning (Oct. 31) that Michel Pettigrew is retiring as president of the executive board and will be succeeded by CSO Per Falk. The two spoke to Scrip recently and outlined the Swiss-based firm's future strategy.
This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Gynecological, Urological
- North America
- Parent & Subsidiaries
- Celmatix Inc.
- Senior Management
Laura Towart Bandak, CEO
Piraye Yurttas Beim, PhD, CSO
Erin Wolff, MD, CMO
Lori Batta, Chief Commercial Officer
- Contact Info
Phone: (646) 389-0245
1 Little West 12th St.
New York, NY 10014
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.